NICE approves ixazomib in combination with lenalidomide–dexamethasone to treat relapsed or refractory multiple myeloma

The National Institute for Health and Care Excellence (NICE) published a guidance document recommending the use of ixazomib (brand name Ninlaro®) in combination with lenalidomide and dexamethasone in patients with refractory or relapsed multiple myeloma. It is estimated that approximately 2000 individuals will be in line to benefit from the new oral therapy following the release of the NICE guidance and is recommended for those who have previously had 2 or 3 treatments. This new combination therapy will be the only oral triple therapy for patients at this certain stage of their treatment regimen. Multiple myeloma is a progressive cancer...